The asx does not rate medtech like the NASDAQ does.I am into AVR as well and they are going to the NASDAQ in the next 6 months as per their agm in order to raise more money and not to be confined by a 15% asx ruling. If they gain 5% of the $10b market they are in and be priced as per their rivals they would have a SP of $600. Presently $19. They like EYE have a better product than the market leader Edwards science as per the data.
Nova Eye Medical (EYE) Discussion, page-2989
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.015(10.3%) |
Mkt cap ! $36.64M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 16.0¢ | 14.5¢ | $38.73K | 257.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 84655 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 271846 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |